Skip to main content
OpenTrials
Completed

NCT Number: NCT00862680

4D PET/CT in Diagnosing Participants With Lung and Colorectal Cancer With Liver and Lung Metastasis

This trial studies how well 4 dimensional (D) positron emission tomography/computed tomography (PET/CT) works in diagnosing participants with lung or colorectal cancer that has spread to the liver and lung. Diagnostic procedures, such as PET/CT, may help find and diagnose disease and find out how far the disease has spread. But the motions made by breathing can reduce the image quality of the scan. Adjusting the scanner to 4D may allow for more breathing motion may improve the quality of the PET/CT images.

Completed

Looking for future studies?

Notify Me

Key information

About this study

PRIMARY OBJECTIVES:

I. Study the impact of 4D positron emission tomography/computed tomography (PET/CT) imaging on the evaluation and staging of lung and colorectal cancer.

OUTLINE:

Participants undergo 4D PET/CT scan over up to 12 minutes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with suspected colorectal cancer with nodules in the lung or liver (1-2 cm in diameter) will be eligible for this study.
  • Patients with suspected lung cancer with nodules in the lung or liver (1-2 cm in diameter) will be eligible for this study.

Exclusion criteria

  • Patients that cannot tolerate being scanned for an additional 12 minutes with arms above their head will be excluded.

Treatment and study plan

4-Dimensional Computed Tomography

Procedure

Undergo 4D PET/CT

Other names: 4D Computed Tomography, 4DCT, Time-Resolved CT Data Acquisition

4D PET Scan

Procedure

Undergo 4D PET/CT scan

Other names: 4D Gated PET, 4D Gated PET Scan, 4D PET

Primary outcomes

  1. Maximum lesion standardized uptake value (SUVmax) for gated and ungated positron emission tomography/computed tomography (PET/CT) scans

    Time frame: Up to 10 years

    Will be compared using a one-sided paired t-test.

  2. Impact of the difference in SUVmax on the lesion detectability and staging of the evaluated patients

    Time frame: Up to 10 years

    two nuclear medicine physicians will assess the impact of the difference in SUVmax on the lesion detectablility and staging of the evaluated patients.

Sponsors and collaborators

Lead sponsor

M.D. Anderson Cancer Center

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Official study title

4D PET/CT Imaging in Lung and Colorectal Cancer With Liver Metastasis

Important dates

Study start
2009
Primary completion
2019
Study completion
2019
First posted
Mar 17, 2009
Registry last updated
Apr 14, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.